Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Moderate to Severe Conjunctivochalasis

Conjunctivochalasis Clinical Trial

Official title:
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Moderate to Severe Conjunctivochalasis

Status Completed

Clinical Trial Summary

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients with Moderate to Severe Conjunctivochalasis

Clinical Trial Description

Phase 2, randomized, placebo-controlled, parallel group, study in up to 62 adult patients with moderate to severe CCh. Eligible patients will be randomly assigned in a 1:1 ratio to one of two treatment groups, LO2A or placebo, stratified by LIPCOF grade at baseline. This study with 4 visits, will consist of a screening period of up to 2 weeks and a 3-month treatment period (topical, OU, QID application of eye drops). ;

Study Design

Related Conditions & MeSH terms

Conjunctivochalasis

Clinical Trial Details

NCT number	NCT02804191
Study type	Interventional
Source	Ocuwize LTD
Contact
Status	Completed
Phase	Phase 2
Start date	July 2016
Completion date	June 2019

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02810119` - To Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Conjunctivochalasis	Phase 2
	Active, not recruiting	`NCT02160327` - The Role of Cytokines and Mast Cell in the Pathogenesis of SLK, Conjunctivochalasis, and Dry Eye	N/A